Molecular Mechanism Identification in Inherited Arrhythmias and Valvulopathies From Induced Pluripotent Stem Cells

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01734356

Acronym

Diag-iPS

Enrollment

Registered

2012-11-27

Start date

2011-11-30

Completion date

2014-11-30

Last updated

2014-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inherited Arrhythmias and Valvulopathies

Keywords

iPS, fibroblast, arrhythmias, valvulopathies, electrophysiology, genetics

Brief summary

The recent developments of research on iPS (induced pluripotent stem) cells lead to the establishment of mature cell lines such as cardiomyocytes or valvular interstitial cells with genetic and cellular characteristics of the donors. These cells represent a biological material more readily available to identify the pathophysiological mechanisms involved in the diseases of BrS or ERS patients, which will lead to the identification of genetic markers.

Interventions

OTHERSkin biopsies

Study design

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

22 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patient with a family history of inherited arrhythmia or valvulopathy * Age : 22-60 yo. * patient no confine to bed * Male or female * Written consent * Patient affiliated to the French social security

Exclusion criteria

* Pregnant woman * Patient under 22 yo or adults under guardianship * Indication against local anesthesia * Anticoagulant treatment * Absence or positivity of HIV, HBV, HCV serology

Design outcomes

Primary

Measure	Time frame
Production of cardiomyocytes modele from skin fibroblast of arrhythmic patient	—

Secondary

Measure	Time frame
Production of valve interstitial cells modele from skin fibroblast of patient with a valvulopathy	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026